Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...

As part of the deal, Eli Lilly will acquire Scorpion's STX-478, an investigative once-daily oral medication being evaluated in a trial. Scorpion would spin out its non-phosphoinositide 3-kinase ...

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a cancer therapy being developed by Scorpion Therapeutics in a third major transaction announced on the first day of the JP Morgan ...

GlaxoSmithKline's head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. Hoos is leaving GSK after nine ...

The American pharmaceutical company Eli Lilly & Co. has entered into an agreement to acquire an experimental antitumor drug developed by Scorpion Therapeutics Inc. This is reported in a press release ...

In a significant move to bolster its pipeline and capabilities, Relay Therapeutics acquired Scorpion Therapeutics in early 2025 for $2.5 billion in cash. This acquisition is viewed by analysts as ...

Two recent high-profile acquisitions exemplify this trend; Eli Lilly’s pursuit of Scorpion Therapeutics and GSK’s acquisition of IDRx. Eli Lilly’s Bold Bid to Lead Oncology Eli Lilly’s ...

AstraZeneca’s partnership with Scorpion Therapeutics will focus on transcription factors that are known to play a role in cancer but have been difficult to target with small molecule drugs.

Additionally, the recent acquisition of Scorpion by Lilly for a significant ... Begin your TipRanks Premium journey today. Relay Therapeutics (RLAY) Company Description: Relay Therapeutics Inc ...

In a significant move to bolster its pipeline and capabilities, Relay Therapeutics acquired Scorpion Therapeutics in early 2025 for $2.5 billion in cash. This acquisition is viewed by analysts as a ...